The clinical consequences of neutrophil priming.
View / Open Files
Publication Date
2019-01Journal Title
Curr Opin Hematol
ISSN
1065-6251
Publisher
Ovid Technologies (Wolters Kluwer Health)
Volume
26
Issue
1
Pages
22-27
Language
eng
Type
Article
This Version
AM
Physical Medium
Print
Metadata
Show full item recordCitation
Vogt, K. L., Summers, C., & Condliffe, A. M. (2019). The clinical consequences of neutrophil priming.. Curr Opin Hematol, 26 (1), 22-27. https://doi.org/10.1097/MOH.0000000000000471
Abstract
PURPOSE OF REVIEW: Neutrophils priming has been long studied in vitro. Recent studies describe it in vivo. In pathophysiological conditions, complex, heterogeneous characteristics of priming are described in the last few years. RECENT FINDINGS: Priming can occur systemically when insults such as sepsis or trauma result in an array of circulating mediators and circulating primed neutrophils seem to exert detrimental effects either directly, or indirectly by interacting with other cells, thereby contributing to the development of organ dysfunction. Local priming of neutrophils augments their ability to clear infection, but may also lead to local bystander tissue injury, for example, in the inflamed joint. The complexity, heterogeneity and dynamic nature of inflammatory responses and the accessibility of cells from local sites make neutrophil priming challenging to study in human disease; however, recent advances have made significant progress to this field. SUMMARY: Herein, we summarize the literature regarding neutrophil priming in selected conditions. In some diseases and in the setting of specific genetic influences, the priming repertoire seems to be restricted, with only some neutrophil functions upregulated. A greater understanding of the nature of neutrophil priming and its role in human disease is required before this process becomes tractable to therapeutic intervention.
Keywords
Humans, Infections, Inflammation, Neutrophil Activation, Neutrophils
Sponsorship
The research in the authors laboratories is funded by the MRC (MR/M012328; MR/P502091/1), British Lung Foundation (PRG16-13), Wellcome Trust, GlaxoSmithKline plc and NIHR Cambridge Biomedical Research Centre.
Funder references
Medical Research Council (MR/M012328/1)
Medical Research Council (MR/P502091/1)
Identifiers
External DOI: https://doi.org/10.1097/MOH.0000000000000471
This record's URL: https://www.repository.cam.ac.uk/handle/1810/286404
Rights
Licence:
http://www.rioxx.net/licenses/all-rights-reserved
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: support@repository.cam.ac.uk